Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of CNS disorders

Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of CNS disorders

PCT No. PCT/PL94/00004 Sec. 371 Date Jul. 26, 1995 Sec. 102(e) Date Jul. 26, 1995 PCT Filed Jan. 24, 1994 PCT Pub. No. WO94/16705 PCT Pub. Date Aug. 4, 1994A method of treating central nervous system diseases and disorders, the diseases and disorders being responsive to drugs possessing psychotropic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: SERWIN-KRAJEWSKA, MARTA, BOGDAL, MARIA, SWIRSKA, ALICJA, KOBYLINSKA, KRZYWOSINSKI, LESZEK, GRZESZKIEWICZ, ANDRZEJ
Format: Patent
Sprache:eng
Schlagworte:
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator SERWIN-KRAJEWSKA
MARTA
BOGDAL
MARIA
SWIRSKA
ALICJA
KOBYLINSKA
MARIA
KRZYWOSINSKI
LESZEK
GRZESZKIEWICZ
ANDRZEJ
description PCT No. PCT/PL94/00004 Sec. 371 Date Jul. 26, 1995 Sec. 102(e) Date Jul. 26, 1995 PCT Filed Jan. 24, 1994 PCT Pub. No. WO94/16705 PCT Pub. Date Aug. 4, 1994A method of treating central nervous system diseases and disorders, the diseases and disorders being responsive to drugs possessing psychotropic activity. The method involves administering to a subject suffering from the disease or disorder a therapeutically effective amount of 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone or a pharmaceutically acceptable salt of 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone. The invention also relates to a pharmaceutical composition, the composition having pharmaceutically acceptable carriers and 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and/or a pharmaceutically acceptable salt of 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US5643907A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US5643907A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US5643907A3</originalsourceid><addsrcrecordid>eNqFjjFqw0AQRdWkCLHPkCmdYiFEVozLIGJSBYPt2ky0I-_A7ozYHUHkc-TAVpHe1fvF-_Aeq799wJywo9G4wwidpkELG6vMWwxZWC7QuKR5CBpZNJGFKbrardauC1Gz_pBcp8iehDCx0It7c_qL11n380EIUDywFRgLQa8ZLBBYJrREYqA9tN8H8Fw0e8plUT30GAst__lUPe8-j-2Xo0HPVIY5V8jOp0Pzvq63r5uP-r5xAweGUFI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of CNS disorders</title><source>esp@cenet</source><creator>SERWIN-KRAJEWSKA; MARTA ; BOGDAL; MARIA ; SWIRSKA; ALICJA ; KOBYLINSKA; MARIA ; KRZYWOSINSKI; LESZEK ; GRZESZKIEWICZ; ANDRZEJ</creator><creatorcontrib>SERWIN-KRAJEWSKA; MARTA ; BOGDAL; MARIA ; SWIRSKA; ALICJA ; KOBYLINSKA; MARIA ; KRZYWOSINSKI; LESZEK ; GRZESZKIEWICZ; ANDRZEJ</creatorcontrib><description>PCT No. PCT/PL94/00004 Sec. 371 Date Jul. 26, 1995 Sec. 102(e) Date Jul. 26, 1995 PCT Filed Jan. 24, 1994 PCT Pub. No. WO94/16705 PCT Pub. Date Aug. 4, 1994A method of treating central nervous system diseases and disorders, the diseases and disorders being responsive to drugs possessing psychotropic activity. The method involves administering to a subject suffering from the disease or disorder a therapeutically effective amount of 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone or a pharmaceutically acceptable salt of 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone. The invention also relates to a pharmaceutical composition, the composition having pharmaceutically acceptable carriers and 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and/or a pharmaceutically acceptable salt of 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone.</description><edition>6</edition><language>eng</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>1997</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=19970701&amp;DB=EPODOC&amp;CC=US&amp;NR=5643907A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=19970701&amp;DB=EPODOC&amp;CC=US&amp;NR=5643907A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SERWIN-KRAJEWSKA; MARTA</creatorcontrib><creatorcontrib>BOGDAL; MARIA</creatorcontrib><creatorcontrib>SWIRSKA; ALICJA</creatorcontrib><creatorcontrib>KOBYLINSKA; MARIA</creatorcontrib><creatorcontrib>KRZYWOSINSKI; LESZEK</creatorcontrib><creatorcontrib>GRZESZKIEWICZ; ANDRZEJ</creatorcontrib><title>Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of CNS disorders</title><description>PCT No. PCT/PL94/00004 Sec. 371 Date Jul. 26, 1995 Sec. 102(e) Date Jul. 26, 1995 PCT Filed Jan. 24, 1994 PCT Pub. No. WO94/16705 PCT Pub. Date Aug. 4, 1994A method of treating central nervous system diseases and disorders, the diseases and disorders being responsive to drugs possessing psychotropic activity. The method involves administering to a subject suffering from the disease or disorder a therapeutically effective amount of 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone or a pharmaceutically acceptable salt of 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone. The invention also relates to a pharmaceutical composition, the composition having pharmaceutically acceptable carriers and 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and/or a pharmaceutically acceptable salt of 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>1997</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqFjjFqw0AQRdWkCLHPkCmdYiFEVozLIGJSBYPt2ky0I-_A7ozYHUHkc-TAVpHe1fvF-_Aeq799wJywo9G4wwidpkELG6vMWwxZWC7QuKR5CBpZNJGFKbrardauC1Gz_pBcp8iehDCx0It7c_qL11n380EIUDywFRgLQa8ZLBBYJrREYqA9tN8H8Fw0e8plUT30GAst__lUPe8-j-2Xo0HPVIY5V8jOp0Pzvq63r5uP-r5xAweGUFI</recordid><startdate>19970701</startdate><enddate>19970701</enddate><creator>SERWIN-KRAJEWSKA; MARTA</creator><creator>BOGDAL; MARIA</creator><creator>SWIRSKA; ALICJA</creator><creator>KOBYLINSKA; MARIA</creator><creator>KRZYWOSINSKI; LESZEK</creator><creator>GRZESZKIEWICZ; ANDRZEJ</creator><scope>EVB</scope></search><sort><creationdate>19970701</creationdate><title>Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of CNS disorders</title><author>SERWIN-KRAJEWSKA; MARTA ; BOGDAL; MARIA ; SWIRSKA; ALICJA ; KOBYLINSKA; MARIA ; KRZYWOSINSKI; LESZEK ; GRZESZKIEWICZ; ANDRZEJ</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US5643907A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>1997</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>SERWIN-KRAJEWSKA; MARTA</creatorcontrib><creatorcontrib>BOGDAL; MARIA</creatorcontrib><creatorcontrib>SWIRSKA; ALICJA</creatorcontrib><creatorcontrib>KOBYLINSKA; MARIA</creatorcontrib><creatorcontrib>KRZYWOSINSKI; LESZEK</creatorcontrib><creatorcontrib>GRZESZKIEWICZ; ANDRZEJ</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SERWIN-KRAJEWSKA; MARTA</au><au>BOGDAL; MARIA</au><au>SWIRSKA; ALICJA</au><au>KOBYLINSKA; MARIA</au><au>KRZYWOSINSKI; LESZEK</au><au>GRZESZKIEWICZ; ANDRZEJ</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of CNS disorders</title><date>1997-07-01</date><risdate>1997</risdate><abstract>PCT No. PCT/PL94/00004 Sec. 371 Date Jul. 26, 1995 Sec. 102(e) Date Jul. 26, 1995 PCT Filed Jan. 24, 1994 PCT Pub. No. WO94/16705 PCT Pub. Date Aug. 4, 1994A method of treating central nervous system diseases and disorders, the diseases and disorders being responsive to drugs possessing psychotropic activity. The method involves administering to a subject suffering from the disease or disorder a therapeutically effective amount of 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone or a pharmaceutically acceptable salt of 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone. The invention also relates to a pharmaceutical composition, the composition having pharmaceutically acceptable carriers and 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and/or a pharmaceutically acceptable salt of 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone.</abstract><edition>6</edition><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_US5643907A
source esp@cenet
subjects CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of CNS disorders
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T08%3A47%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SERWIN-KRAJEWSKA;%20MARTA&rft.date=1997-07-01&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS5643907A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true